GENEVA, April 20 -- Biaoyang Lin and Gregory Foltz, both of the U.
S., have developed a method for diagnosis, prognosis and treatment of glioblastoma multiforme.
The patent has been assigned to Swedish Health Services, Seattle.
According to an abstract posted by the World Intellectual Property Organization: 'The present invention in one aspect relates generally to the identification, provision and use of a plurality of biomarkers to provide risk assessment of a subject having glioblastoma multiforme, and products and processes related thereto. In one aspect, a novel plurality of biomarkers as described herein is provided to determine a risk of glioblastoma multiforme. In another aspect, a novel plurality of biomarkers as described herein is provided to diagnose a subject having glioblastoma multiforme. In yet another aspect are methods for treating a subject having glioblastoma multiforme by administering one or more therapeutic regimens for glioblastoma multiforme. In yet another aspect are nucleic acid arrays comprising nucleic acid probes that hybridize to one or more glioblastoma multiforme genes.'
The invention carries International Patent Publication No. WO/2010/042831 on April 15.
The original patent was filed in the U.
S. under application No. PCT/US2009/060185 on Oct. 9, 2009. It is available at: http://www.wipo.int/pctdb/en/ia.jsp?ia=US2009/060185 For more information about US Fed News contract awards please contact: Sarabjit Jagirdar, US Fed News, Email:- htsyndication@hindustantimes.com.
